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ABSTRACT
Differentiation therapy is an attractive treatment for osteosarcoma (OS). CD99 is a cell surface molecule expressed in mesenchymal
stem cells and osteoblasts that is maintained during osteoblast differentiation while lost in OS. Herein, we show that whenever OS
cells regain CD99, they become prone to reactivate the terminal differentiation program. In differentiating conditions, CD99‐
transfected OS cells express osteocyte markers, halt proliferation, and largely die by apoptosis, resembling the fate of mature
osteoblasts. CD99 induces ERK activation, increasing its membrane‐bound/cytoplasmic form rather than affecting its nuclear
localization. Through cytoplasmic ERK, CD99 promotes activity of the main osteogenic transcriptional factors AP1 and RUNX2, which
in turn enhance osteocalcin and p21WAF1/CIP1, leading to G0/G1 arrest. These data underscore the alternative positions of active ERK
into distinct subcellular compartments as key events for determining OS fate. © 2014 The Authors. Journal of Bone and Mineral
Research published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research. This is an open access
article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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Introduction
Osteosarcoma (OS) is the most frequent primary malignan-cy arising from bone in children and young adults. Thus, in
spite of the relative rarity (approximately 400 new cases per
year in the United States), its social impact is particularly
relevant. Although targeted therapies have revolutionized the
therapeutic approach to carcinomas, translation of selective
inhibitors—ranging from small molecules to monoclonal
antibodies—has been slow or poorly effective in the treatment
of OS.(1) The presence of complicated structural and numeric
genomic rearrangements in OS cells, redundancy of autocrine
loops and kinase activations,(2) as well as the rarity of the tumor
that hinders extensive understanding of the genetic and
biologic features of OS have precluded any effective applica-
tion of targeted agents. It is thus not surprising that the only
drug approved for the treatment of OS patients in the recent
years is indeed the immunomodulator mifamurtide (liposomal
muramyl tripeptide phosphatidyl ethanolamine [L‐MTP‐PE]),
which activates macrophages and monocytes and presents
broad, although poorly characterized, mechanisms of action.(3)
Despite the considerable interest, debate about whether the
addition of L‐MTP‐PE to standard chemotherapy regimens truly
results in a proven benefit is ongoing, and patients with OS still
substantially lack new effective drugs. Systemic treatments
continue to be based on the use of methotrexate, doxorubicin,
and cisplatin, with possible inclusion of ifosfamide or etopo-
side; thus, patients achieved a 65% to 75% survival rate(4) by
paying the price of severe toxicity and high risk of life‐
threatening late side events. Survivors of sarcomas, together
with those of brain tumors, have the lowest health quality‐of‐
life scores(5) and high cure costs, owing to limb‐salvage
procedure, prolonged dose‐dense chemotherapy (around 1
year), and development of chronic severe pathologies. Thus,
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even in the best conditions of localized tumors at diagnosis, we
need complementary therapeutic approaches to help keep
treatment‐related toxicity to a minimum and to optimize
systemic‐disease control.
OS is characterized by proliferation of malignant cells with
osteoblastic features and defined by the presence of uncalci-
fied bone matrix (osteoid). Transformation is thought to occur
in mesenchymal stem cells (MSCs) and/or osteoprogenitors in
any phases of their differentiation(6,7) and generates a block in
normal development coupled with unregulated proliferation
processes.(8) The loss of differentiation is a widespread
biological feature of OS and has a strong prognostic
significance; conventional OSs are high grade and poorly
differentiated lesions. However, well‐differentiated variants
exist, and these tumors are classified as low‐grade OSs,
showing a much more favorable clinical history.(9) Differentia-
tion of high‐grade OS cells can be stimulated in vitro and leads
to reversal of malignancy,(10) confirming that differentiation
may serve as a critical clinical and biologic transition of a fatal
cancer into one more amenable to management or to
treatments. Thus, as for leukemia, differentiative therapy might
also be a valid option for sarcomas, if essential recruited
molecular pathways were understood. In this article, we focus
on CD99, a cell surface molecule that we have demonstrated to
serve as a new crucial modulator of OS malignancy.(11,12) CD99
is a 32‐kDa transmembrane glycoprotein encoded by the
pseudoautosomal MIC2 gene,(13–16) which contains an extra-
cellular domain, followed by a transmembrane domain and a
short 36‐amino acid intracytoplasmic domain. Despite CD99
having a key role in several biological processes (including cell
adhesion, migration, and apoptosis, differentiation of T cells
and thymocytes, diapedesis of lymphocytes to inflamed
vascular endothelium, maintenance of cellular morphology,
and regulation of intracellular membrane protein traffick-
ing),(17–19) its functions appeared to be cell‐context dependent,
and we still know little about how the molecule works.
Although the mouse homologue of CD99 (designated D4)
seems to act through its ligand, the paired immunoglobulin‐
like type 2 receptor (PILR),(20) homophilic interactions among
CD99 molecules seem to be required to trigger signaling of
human CD99.(21) Broadly expressed in normal tissues, CD99 is
differentially expressed in neoplasms, with a strong expression
in some pediatric tumors, such as Ewing’s sarcoma and acute
lymphoblastic leukemia cells,(22,23) and a low, but broad,
distribution in many other neoplastic cell types, including
osteosarcoma.(11,12) Our previous work has shown that forced
expression of CD99 in OS manages to increase cell adhesion
and reactivate stop‐migration signals that result in significant
reduction of metastasis.(11,12,24) In this article, we analyzed the
possible relationship between CD99 and osteoblastic differen-
tiation. Sporadic information suggested a possible involve-
ment of CD99 in bone pathophysiology; Bertaux and
colleagues(25) pointed out a link between CD99 and the
transcription factor RUNX2, which is the master gene of
osteoblastogenesis. In addition, Hamilton and colleagues(26)
found that supernatants from several cancer cell lines
specifically downregulated CD99 on trabecular osteoblasts
(AHTO‐7 cells), while inducing osteoblast activation and
proliferation. In this article, we provide evidence that CD99
is expressed in human MSCs and mature human osteoblasts
and its expression increases during normal osteoblasto-
genesis and osteoblast maturation. When CD99 is restored in
OS cells, the molecule switches cells from proliferation status to
cell cycle withdrawal, favoring the achievement of a terminally
osteoblast‐differentiated phenotype. Cell death and expres-
sion of osteocyte markers accomplish the process. From a
mechanistic point of view, we propose that CD99 increases
MAPK/ERK signaling and recruits activated ERK to cell
membrane/cytoplasm, where it may phosphorylate RUNX2,




TheOS cell lines U‐2 OS and Saos‐2 were obtained from American
Type Culture Collection (Manassas, VA, USA). The IOR/OS7,
IOR/OS9, IOR/OS14, IOR/OS15, IOR/OS17, and SARG cell lines
were established at the Laboratory of Experimental Oncology,
Rizzoli Orthopedic Institute (Bologna, Italy) and previously
characterized.(27) All cell lines were tested for mycoplasma
contamination every 3 months (last control June 2013) by PCR
Mycoplasma detection Set (Takara Bio Inc., Shiga, Japan). Stable
transfectants expressing CD99 were obtained from the Saos‐2,
IOR/OS7, or U‐2 OS cell lines (Sa/CD99wt22, Sa/CD99wt36,
OS7/CD99wt8, OS7/CD99wt89, and U2/CD99wt136) by using
calcium‐phosphate transfection method. Cell lines and trans-
fectants were grown as previously described.(11) Human primary
bone marrow–derived mesenchymal stem cells (hBM‐MSCs)
(Table 1) were isolated, cultured, and characterized as de-
scribed.(27) Primary cultures of human osteoblasts were obtained
from fragments of cortical and spongy trabecular bone and
maintained in 10% FBS a‐MEM for 2 weeks before analysis.(28)
Human bone‐derived cells converted into OS cells by over-
expression of the MET oncogene(29) were also used.
Osteoblast differentiation
Four days after cell seeding, cells were exposed to specific
osteogenic medium (IMDM for OS cells, or a‐MEM for primary
human osteoblasts and hBM‐MSCs), supplemented with 2%
fetal bovine serum (FBS), 5mM b‐glycerophosphate, and
50mg/mL ascorbic acid (Sigma‐Aldrich, St. Louis, MO, USA)
and maintained in differentiative conditions for 21 to 28 days.
Medium was renewed every 4 days. Cultures were harvested at
various time points to collect total RNA or proteins. Osteoblast
differentiation was verified by evaluation of specific markers by
quantitative real‐time PCR (qRT‐PCR), by liver/bone/kidney
alkaline phosphatase (ALP) activity, as well as bone mineraliza-
tion. Total RNA from differentiated OS cell lines was extracted
using the Trizol extraction kit (Life Technologies, Grand Island,
NY, USA). qRT‐PCR was performed as described.(11) All primers
used are indicated in Supplemental Table S1. For a more
general view on osteogenic differentiation of the OSmodel, the
Human Osteogenesis RT2 Profiler PCR Array (Qiagen‐SABio-
sciences, Valencia, CA, USA) was also used. ALP activity was
assessed using p‐nytrophenyl phosphate as a substrate
(Boehringer Mannheim, Mannheim, Germany) as previously
described.(30) To visualize bone mineralization in primary
cultures as well as in OS cells, duplicate plates were stained
with 2% AgNO3 (von Kossa staining) or with 40mM Alizarin Red
S (ARS staininig) (all from Sigma‐Aldrich). To quantify bone
mineralization assessed for CD99‐overexpressing transfectants
and the respective parental cell lines, ARS was extracted from
the monolayer by incubation with 10% cetylpyridinium
chloride (CPC; Sigma‐Aldrich). The dye was then removed,
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and 200mL was transferred to a 96‐well plate for reading at
550 nm.
Cell growth and proliferation
Growth was monitored in differentiating conditions by
methylene blue staining (Sigma‐Aldrich), which exploits
the ability of the dye to intercalate to DNA. Cells were fixed in
10% formalin and then exposed to a solution of 1%
methylene blue in 0.01 M borate buffer. The extracted dye
with 0.1 M HCl–absolute EtOH (1:1) was quantified by
spectrophotometer reading (655 nm). Vital count was
performed by using the vital dye Trypan Blue. Bromodeox-
yuridine (BrdU) labeling was used to assess cell proliferation.
Briefly, cells were exposed to 10 mM BrdU for 1 h before being
fixed in 70% ethanol. After DNA denaturation and washing,
cells were processed for indirect immunofluorescence
staining using anti‐BrdU MAb (1:4; Becton Dickinson, Milan,
Italy) as a primary antibody. For immunohistochemistry,
avidin–biotin–peroxidase procedure was used (Vector Lab-
oratories, Burlingame, CA, USA). For cell cycle analysis,
cells were stained with the anti‐mouse FITC secondary
antibody (1:100; Thermo Scientific, South Logan, OH, USA)
and 20 mg/mL propidium iodide before flow cytometric
analysis (FACSCalibur; Becton Dickinson).
Western blotting
Western blotting experiments were performed as previously
described using total protein lysates or fractionated pro-
tein.(11,31) The following antibodies were used: anti‐CD99 12E7
(1:4000; Dako, Carpinteria, CA, USA), anti‐p21 (1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti‐ERK 1/2 (1:3000;
Cell Signaling Technology, Beverly, MA, USA), anti‐phospho‐
ERK 1/2 Thr202/Tyr204 (1:1000; Covance, Princeton, NJ, USA).
Membranes were incubated with secondary anti‐mouse or
anti‐rabbit antibodies conjugated to horseradish peroxidase
(GE Healthcare, Piscataway, NJ, USA) and revealed by ECL
Western blotting detection reagents (Euroclone, Milan, Italy).
Loading control and purity of fractionated lysates were
assessed by anti‐GAPDH (1:3000; Santa Cruz Biotechnology)
or anti‐actin (1:200,000; Merck Millipore, Billerica, MA, USA),
and anti‐Lamin B (1:3000; Santa Cruz Biotechnology) after
stripping.
Table 1. Evaluation of CD99 Expression by Flow Cytometry in hBM‐MSCs and Their Origin
hBM‐MSC % CD99 Log mean Origin
hBM‐MSC 85 99% 77 GCT of proximal femur
hBM‐MSC 87 99% 61 Pigmented villonodular synovitis in right hip
hBM‐MSC 91 74% 78 Isthmic spondylolisthesis
hBM‐MSC 93 77% 65 Low‐grade osteosarcoma in right distal femur
hBM‐MSC 95 78% 83 Right buttock synovial sarcoma
hBM‐MSC 96 99% 107 Chondromatosis in multiple exostosis
hBM‐MSC 98 70% 10 Ewing’s sarcoma in left iliac wing
hBM‐MSC 102 99% 166 Delay of graft joining in left humerus
hBM‐MSC 110 83% 82 Right proximal humerus bone cyst
hBM‐MSC 111 Negative Left proximal humerus bone cyst
hBM‐MSC 112 74% 75 Heterotopic ossification in concussion
hBM‐MSC 113 28% 30 Right proximal femur bone cyst
hBM‐MSC 114 34% 32 Right proximal humerus bone cyst
hBM‐MSC 115 75% 54 Left humerus diaphysis bone cyst
hBM‐MSC 118 Negative Right humerus diaphysis bone cyst
hBM‐MSC 119 Negative Right proximal humerus bone cyst
hBM‐MSC 121 40% 45 Left acetabular chondrosarcoma
hBM‐MSC1 24 46% 25 Revision of intercalary prosthesis of femur
hBM‐MSC 128 84% 30 Right proximal humerus bone cyst
hBM‐MSC 140 6% 10 Left proximal humerus bone cyst
hBM‐MSC 141 18% 16 Left proximal humerus bone cyst
hBM‐MSC 143 Negative Right L4 paravertebral neurinoma
hBM‐MSC 144 20% 40 Femur osteosarcoma
hBM‐MSC 145 24% 12 Left gluteal leiomyosarcoma
hBM‐MSC 196 97% 79 Right hip exostoses
hBM‐MSC 194 99% 58 Left proximal humerus exostoses
hBM‐MSC 198 99% 57 Right femur consolidation delay
hBM‐MSC 204 98% 61 Left proximal humerus bone cyst
hBM‐MSC 223 100 21 Left knee osteochondritis
hBM‐MSC 168 94% 35 Left proximal femur angiosarcoma
hBM‐MSC 163 98% 41 Left proximal femur fibrous dysplasia
hBM‐MSC 205 70% 23 Left proximal femur homoplastic graft consolidation delay
hBM‐MSC 244 99% 54 Left tibia consolidation delay
hBM‐MSC 249 99% 61 Left distal femur consolidation delay
All the cultures were used within 5 in vitro passages.
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CD99 expression
CD99 expression was evaluated at mRNA by gene expression
profiling by using Illumina DNA chips and Illumina BeadArray
Reader (Illumina Inc., San Diego, CA) as described.(6) CD99
expression was analyzed at protein level also by indirect
immunofluorescence on a FACSCalibur flow cytometer. The O13
MAb (1:80; Covance) and anti‐mouse FITC (1:100; ThermoScientific)
were used as primary and secondary antibodies, respectively.
Apoptosis analysis
The Tunel assay (ApoTag Plus Peroxidase In Situ Apoptosis
Detection Kit, Millipore Corporation, Bedford, MA, USA) was used
to evaluate apoptosis in adherent cells during differentiation
according to the manufacturer’s instructions.
Chromatin immunoprecipitation (ChIP) assay
Cells were collected in basal and differentiating conditions (at
day 7 of differentiation). ChIP assay was performed as previously
described.(19) The immuno‐cleared chromatin was precipitated
with anti‐RUNX2 (M‐70; Santa Cruz Biotechnology) antibody.
Two microliters of initial preparations of soluble chromatin
were amplified to control input DNA. The following pairs of
primers were used to amplify RUNX2‐containing promoters of
target genes: OCN promoter (221 bp) 5’‐GGGGGTCTCTGAG-
GAAGAGT‐3’ (forward) and 5’‐GAATCTGCCAGGGCTATTTG‐3’
(reverse); p21WAF/CIP1 promoter (215 bp): 5’‐GGTCAGGGGTGT-
GAGGTAGA‐3’ (forward) and 5’‐CACAGGACTTTTGCCTCCTG‐3’
(reverse). Amplification products were analyzed in 1.5% agarose
gel and visualized by ethidium bromide staining. The signal was
quantified by using GS‐800 imaging densitometer (Bio‐Rad,
Hercules, CA, USA) and the Quantity One 4.6.9 software (Bio‐
Rad). ChIP products were also quantified by qRT‐PCR using the
same amount (100 ng) of IP and total DNA in a 25mL reaction
containing Sybr Green master mix and 300 nM of forward and
reverse primers. Data were represented as recovery, in percent,
of each DNA fragment relative to total input DNA, and it was
calculated as previously described.(32)
Luciferase reporter gene assay
Cells were seeded in standard medium in 24‐well plates (5 104
per well). At 70% confluence, the cultures were transfected with
250ng of the SRE and AP1 reporter assays (Cignal SRE and AP1
Reporter kit; Quiagen‐SA Biosciences) using Lipofectamine 2000
(Life Technologies). The mixture also contains a constitutively
expressing Renilla luciferase construct to assess transfection
efficacy. Forty‐eight hours after transfection, cells were lysed, and
luciferase activity was measured according to the manufacturer’s
protocol using the Dual‐Glo Luciferase Assay System (Promega,
Madison, WI, USA) with a GloMax Luminometer (Promega). To
evaluate growth stimulatory effects, cells were starved overnight
and then exposed to IGF1 (50ng/mL; Merck Millipore) for 1 hour
before luciferase activitywas assessed, 24 hours after transfection.
Immunofluorescence on adherent cells
Cells were grown on coverslips and fixed in 4% paraformalde-
hyde (for RUNX2) or 0.5% formalin and 90% methanol (for
phospho‐ERK 1/2). After permeabilization with 0.15% Triton X‐
100 in PBS, cells were incubated with the following antibodies:
anti‐phospho ERK 1/2 (phospho Thr202/Tyr204) (1:10; Covance)
and anti‐RUNX2 (1:10; 27‐k, Santa Cruz Biotechnology). Nuclei
were counterstained with Hoechst 33258. The stained sections
were visualized using the microscope Nikon (Tokyo, Japan)
ECLIPSE 90i equipped with a Plan Apo VC 60 oil, NA 1.4, at RT.
Images were captured under identical conditions using a digital
color camera (Nikon DS5MC) and the software NIS‐Elements AR
3.10 (Nikon). The same software was used to merge all images
with double labeling.
Treatment with ERK 1/2 inhibitors
The ERK inhibitor PD98059 (50mM; Merck Millipore) was added
to differentiation medium and renewed with osteogenic
medium every 3 to 4 days. Cell growth and bone mineralization
were assessed bymethylene blue or ARS staining, respectively. In
basal conditions, inhibition of ERK 1/2 activation was checked by
immunofluorescence on adherent cells grown on coverslips.
Standard medium was replaced by IMDM plus 10% FBS with or
without (control) PD98059 (50mM), U0126 (10mM; Cell Signal-
ing), and its inactive analog U0124 (10mM; Merck Millipore). The
phosphorylation of ERKwas assessed after 24 hours of treatment.
To evaluate the effects on the transcriptional activities of ELK‐1
and AP1 after ERK inhibition, cells were starved overnight and
treated with PD98059 (100mM) for 2 hours. Luciferase activity
was checked 24 hours after transfection.
Treatment with siRNA against CD99
Transient CD99‐silencing was assessed by siRNA (5’‐GGCUGGC-
CAUUAUUAAGUCTT‐3’) (IDT, Coralville, IA, USA). Scrambled (ON‐
TARGETplus siCONTROL, Thermo Scientific) and a Validated
STEALTH siRNA (Life Technologies) against p53 were used as
controls. All were administered at a final concentration of 40 nM.
Cells were seeded on coverslips in 60‐mm plates in standard
medium (3 105 cells per plate) and transfected after 24 hours
by using Lipofectamine 2000 (Life Technologies). The expression
of CD99, phospho‐ERK 1/2, or RUNX2 was checked by Western
blotting or by immunofluorescence on fixed cells, treated for 48
hours with siRNA sequences.
Metastatic ability in athymic mice
Female athymic 4‐ to 5‐week‐old Crl:CD‐1‐nu/nu BRmice (Charles
River Italia, Como, Italy) were used. To obtain natural killer
depressed animals, mice were injected iv with anti‐asialo GM1
antiserum 24 hours before cell inoculation. Metastases were
determined by injection of 2 106 viable cells in a tail lateral vein,
and the number of lung colonies were obtained by countingwith
a steromicroscope after staining with black India ink. All animal
experiments were performed according to Italian law 116/92 and
European directive 2010/63/UE. Experimental protocols were
reviewed and approved by the Institutional Animal Care and
Use Committee (“Comitato Etico Scientifico per la Sperimenta-
zione Animale”) of the University of Bologna, and forwarded to
the Italian Ministry of Health.
Statistical analysis
Differences among means were analyzed using Student’s t test.
Results
CD99 is expressed in both hBM‐MSCs and osteoblasts as
part of normal osteoblast differentiation
Protein expression of CD99 was observed at high levels in 24/34
(70%) and atmedium/low levels in 6/34 (18%) of hBM‐MSCs. Only
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4/34 primary cultures were found to be negative (Table 1).
Double‐labeling staining with CD99 and CD166, CD105, or CD29
confirmed that cells expressing mesenchymal markers actually
correspond to those expressing CD99 (Supplemental Fig. S1A).
The latter was also expressed in human osteoblasts,(11) but
it was downregulated when normal bone‐derived cells were
transformed by the MET oncogene (Supplemental Fig. S1B).
Accordingly, patient‐derived OS cell lines exhibited lower levels
of the antigen compared with normal osteoblasts (Supplemental
Fig. S1C). OS cells transduced with CD99 showed reduced
aggressiveness in nude mice(11) (Table 2), according to its
putative oncosuppressive role.
To sustain the involvement of CD99 in osteoblast physiology,
representative cultures of hBM‐MSCs (Fig. 1A) or of human bone
fragment–derived osteoblasts (Fig. 1B) were driven to differenti-
ate toward the osteoblastic lineage. Expression of some specific
osteoblast markers, such as ALP and osteocalcin (OCN),(33) as well
as the production of bone matrix were investigated to verify the
acquisition of the osteoblastic phenotype. CD99 expression
increased during differentiation and was particularly high at the
end of osteoblastic induction when cells became mature.
CD99 expression favors terminal differentiation of
OS cells
To investigate the role of CD99 in OS cell differentiation, we took
advantage of the Saos‐2 and IOR/OS7 cell lines, both displaying
osteoblast‐like features and ability to differentiate toward the
osteogenic lineage in low‐serum medium containing ascorbic
acid (50mg/mL) and b‐glycerophosphate (5mM)(27) (Fig. 2A–C).
Osteoblasts produce and secrete proteins that constitute the
bone matrix, such as collagens and OCN, and are essential for
osteoid matrix mineralization, a process mediated by ALP. OS
cells overexpressing CD99 (Supplemental Fig. S2) had higher
expression of type 1 collagen, ALP, and OCN, early and late
markers of osteoblastic differentiation, respectively (Fig. 2A), and
displayed higher ALP expression and activity (Fig. 2A, B). Such
cells produced more mineralized matrix compared with parental
cells, a difference that became clearly evident whenever
mineralization was normalized by cell number (Fig. 2C). In
addition, consistent with the achievement of a terminal
differentiation, OS cells overexpressing CD99 showed increased
mRNA levels of dentin matrix protein 1 (DMP1) and matrix
extracellular phosphoglycoprotein (MEPE) (Fig. 2D; Supplemen-
tal Fig. S3), two proteins highly expressed by osteocytes,
which are the post‐mitotic cells essential for the physiologic
maintenance of bone homeostasis and integrity.(34) OS cells
overexpressing CD99 were also characterized by decreased
expression of the master regulators Nanog and OCT3/4 mRNA in
basal conditions (Fig. 2D; Supplemental Fig. S3). Both Nanog and
OCT3/4 play a pivotal role in maintaining stemness cell
properties,(35) and their decrease in CD99‐overexpressing cells
is in line with the acquisition of a phenotype more predisposed
to differentiation.
CD99 promotes the transition from proliferation to cell
cycle exit for terminal differentiation of OS cells
Osteoblast differentiation is associated with progressive loss of
proliferative capacities, culminating in their complete block
when mature osteoblasts are embedded in the bone matrix to
become osteocytes.(33) The physiologic coupling of osteoblast
differentiation to inhibition of proliferation is disrupted in OS
cells. In fact, although Saos‐2 and IOR/OS7 OS cells were capable
of osteoblastic differentiation with generation of bone matrix
and expression of mature osteoblast markers such as OCN,
they continued to grow with an exponential trend despite being
kept in differentiating conditions (Fig. 3A). This behavior was
corrected by transfecting OS cells with CD99 that indeed
provided growth restriction and progressive decrease of OS cell
viability along with differentiation (Fig. 3A). The reduction of
tumor cell growth was attributable both to inhibition of cell cycle
progression and to induction of apoptosis. CD99‐transfected
cells showed a higher percentage of cells in the G1 phase of the
cell cycle at the expense of the S phase (Fig. 3B, C). Cell growth
arrest in CD99‐overexpressing cells was supported by increased
expression of p21WAF1/CIP1 (Fig. 3D), a key regulator of G0/G1
proliferative arrest.(36) Induction of p21WAF1/CIP1 was also
observed in normal hBM‐MSCs driven to osteoblast differentia-
tion (Fig. 3D), marking the proliferative block that preludes
terminal differentiation.
Permanent cell cycle withdrawal is a feature of senescence
other than terminal differentiation.(37) CD99‐overexpressing cells
did not stain for senescence‐associatedb‐galactosidase activity(38)
(data not shown). Rather, TUNEL assay clearly showed massive
induction of apoptosis in cells overexpressing CD99 during
differentiation (Fig. 4). Starting from day 7, clustered apoptotic
nuclei, in brown, were evident in CD99‐transfected cells but not in
parental cells, which showedmoderate presenceof apoptotic cells
only at day 21.
CD99 effects are mediated by modulation of MAPK/ERK
signaling and RUNX2 activity
It has been reported that CD99 can induce a differential
activation of the three MAPK members, ERK, JNK, and p38
MAPK.(39–41) We explored the possible involvement of ERK/MAPK
in CD99‐mediated osteogenic effects. This pathway has been
shown to be activated in the osteogenic program;(42) accordingly,
we found activation of ERK 1/2 in normal hBM‐MSCs during
osteoblast differentiation (Fig. 5A). In OS, CD99‐restored
expression resulted in the activation of ERK 1/2 either in basal
and differentiating conditions (Fig. 5A, B). Weaker or no
activation was reported for parental cell lines. Besides being
expressed in the nucleus, where it may activate transcriptional
factors and nuclear phosphatases,(43) phosphorylated ERK 1/2
was particularly evident at the plasma membrane/cytoplasm of
CD99‐expressing cells (Fig. 5B, C), where it may target proteins
that regulate cell adhesion, cell–cell communication, and cell
survival rather than impact on proliferative signals.(44) We
analyzed some of the transcription factors known to be
phosphorylated upon ERK 1/2 translocation into the nucleus
by luciferase assay. In basal conditions, AP1 (Fos/Jun), a key factor
in bone formation,(45) but not ELK‐1 transcriptional activity, was
significantly increased by CD99 transfection in comparison to
parental cells (Fig. 5D). Treatments with PD98059, a selective
inhibitor of theMAPK‐activating enzymeMEK, and, consequently,
of ERK 1/2 translocation into the nucleus, decreased ELK‐1
transcriptional activity when cells were exposed to insulin‐like
Table 2. Metastatic Ability of Saos‐2 Parental Cells and Sa/CD99
Transfected Clones
Cell line Incidence(%) Median (range)
Saos‐2 5/10 (50) 0.5 (0–15)
Sa/CD99wt22 3/9 (33) 0 (0–4)
Sa/CD99wt36 0/10 (0) 0
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growth factor‐1 (IGF1) and increased AP1 transcriptional activity
either in basal conditions or after stimulation with IGF1
(Supplemental Fig. S4A). On one side, this confirmed that
increased AP1 transcriptional activity in CD99‐overexpressing
cells was not related to a proliferation stimulus, whereas on the
other side suggested that AP1 was not a direct target of nuclear
ERK 1/2 in this cellular context. Consistently with luciferase
evidence, PD98059 given in differentiating conditions reduced
cell proliferation of Saos‐2 more effectively than the CD99‐
transfected counterpart (43% versus 12% of growth inhibition at
day 7) but did not modify or even slightly increase levels of
differentiation both in parental and in Sa/CD99 cells (Supple-
mental Fig. S4B, C). In keeping with its described activity,(46)
PD98059 inhibited active nuclear ERK but poorly affected plasma
membrane/cytoplasmic activity of ERK 1/2 in Sa/CD99 cells
(Supplemental Fig. S5), which may still impact OS cell differentia-
tion. In fact, cytoplasmic ERK 1/2 may phosphorylate either
RUNX2, the master gene of osteoblastogenesis, and/or the BMP2
signaling mediators SMADs,(42) which upon translocation to the
nucleusmay activate the transcriptional factor AP1 described as a
Fig. 1. CD99 expression during osteoblast differentiation in hBM‐MSCs (A) and human osteoblasts (hOBs) (B). For both cultures, expression of specific
markers of differentiation in RT‐PCR are shown. Relative expression of alkaline phosphatase (ALP) or osteocalcin (OCN) mRNA was calibrated on
undifferentiated cells at day 0 (2‐DDCT¼ 1). Data are presented as mean SEM of experiments performed in triplicate. Student’s t test was used (p< 0.05;
p< 0.01). Alizarin Red S (ARS), ALP, and von Kossa stainings were performed as described in Materials and Methods to evaluate cellular differentiation
and matrix mineralization. CD99 expression was detected by Western blotting.
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Fig. 2. CD99 drives OS cells toward a terminally osteoblast differentiated phenotype. (A) qRT‐PCR expression of representative osteoblast differentiation
markers in CD99‐overexpressing clones and parental cell lines: collagen 1, ALP, and OCN are displayed to sign early and late stages of the differentiation
process. The relative expression of target mRNA was calibrated on undifferentiated cells at day 0 (2‐DDCT¼ 1). Data are presented as mean SEM of
experiments performed in triplicate. Student’s t test was used (p< 0.05; p< 0.01). (B) Evaluation of ALP expression by histochemical analysis (left panel)
and activity in supernatants (right panel) data are presented as mean SEM of two separate experiments. Student’s t test was used (p< 0.05). (C) ARS
staining of mineralized cultures over 0 to 21 days in differentiationmedium. On the right of the panel, production of bonematrix corrected by cell number
is shown. (D) qRT‐PCR expression of the osteocyte markers DMP1 and MEPE during differentiation (days 14 and 21) and of Nanog and OCT3/4 in basal
conditions (day 0). The relative expression of target mRNA was calibrated on the parental cell line (2‐DDCT¼ 1). Data are presented as mean SEM of
experiments performed in triplicate. Student’s t test was used (p< 0.05; p< 0.01).
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Fig. 3. CD99 inhibits proliferation of OS cells in differentiating conditions. (A) Evaluation of cell growth by methylene blue staining in differentiating
conditions. Data are presented as mean SEM of three separate experiments. Analysis of cell growth was also performed by vital count with Trypan blue.
(B) Cell proliferation evaluated by cell cycle analysis at day 7 of differentiation using flow cytometry. (C) BrdU labeling index evaluated by immuno-
histochemistry at days 0 and 14. Values are expressed asmean% SEM. Student’s t test was used. Ns¼not significant. (D) Modulation of p21WAF1/CIP1 during
osteoblast differentiation. Expression of the same protein in hBM‐MSCs induced to differentiate toward osteogenic program is also shown.
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co‐activator of RUNX2 during osteoblast differentiation.(42) We
did not find significant differences in the expression of RUNX2 at
the mRNA level between parental and CD99‐overexpressing cells
either in basal or in differentiating conditions (Supplemental
Fig. S6). In contrast, at the protein level, RUNX2 was found to be
increased (Fig. 6A) in OS cells ectopically expressing CD99,
consistent with its stabilization owing to ERK‐mediated post‐
translational modifications.(42) RUNX2 expression and localization
in a representative culture of hBM‐MSCs was also shown (Fig. 6A)
for comparison, confirming that whenever MSCs were differenti-
ated in osteoblasts, RUNX2 was increasingly expressed and
localized in the nucleus. Moreover, chromatin immunoprecipita-
tion (ChIP) indicated that the amount of RUNX2 bound to the
promoter of the target genes OCN and p21WAF/CIP1 was augmen-
ted in CD99‐overexpressing compared with parental cells
(Fig. 6B, C). This increase was indeed confirmed also after treat-
ments with PD98059 (þ59% for OCN andþ200% for p21WAF/CIP1
promoters in CD99 cells), which only partially inhibited
cytoplasmic ERK. To verify that the increase of ERK 1/2 and
RUNX2 activity was dependent on increased expression of CD99
and to exclude other nonspecific effects, we performed rescue
knockdown experiments. OS cells expressing the CD99 construct
were transiently transfected with a CD99‐targeting siRNA,(19) with
scrambled siRNA or p53 siRNA, which was used as additional
control considering that both Saos‐2 and IOR/OS7 have p53
deleted. When CD99 expression was inhibited (Fig. 7A), cyto-
plasmic and plasma membrane expression of phospho‐ERK 1/2
was also remarkably decreased (Fig. 7A–C) and the RUNX2 level
was back to that of parental cells (Fig. 7B, C). Accordingly, cells
silenced for CD99 expression showed lower levels of collagen 1
and ALP (Fig. 7D), two early markers of osteoblastic differentia-
tion, further confirming the functional connections between
CD99‐pERK‐RUNX2 axis and differentiation in OS cells. To further
support the specificity of the relationship between sustained
cytoplasmic ERK 1/2 activation and RUNX2, cells were also
exposed to theMEK inhibitor U0126 and its inactive analogU0124
(Supplemental Fig. S5). According to the higher affinity and
selectivity for MEK of U0126 over PD98059, we observed a
complete inhibition of nuclear and cytoplasmic ERK 1/2 that went
in parallel with decreased RUNX2 expression in the nucleus.
Discussion
Differentiation therapy aims at reactivating endogenous differ-
entiation program in cancer cells toward tumor cellular
maturation and concurrent reversal of a fatal cancer into one
more amenable to management. So far, positive examples of
agents able to reverse the tumorigenicity of cancer cells and
place them back on the road to normal differentiation are limited
to acute promyelocytic leukemia.(47) However, unlike other solid
tumors, sarcomas could be reprogrammed to resume normal
differentiation, as recently described in high‐grade undifferenti-
ated pleomorphic sarcoma and liposarcoma by using PPAR-
gamma agonists.(48) A serious limit in the identification of new
therapies is that OS has not been studied extensively as other
cancers with multiple rearrangements that have been proven
responsive to novel strategies. In this article, we sought to
ameliorate the knowledge in the field, shedding new light on a
still poorly understood molecule that is lost in the majority of OS
or after MET‐driven osteoblast transformation but present in
normal osteoblasts and in hBM‐MSCs. During differentiation,
osteoblasts and hBM‐MSCs maintained and even increased the
Fig. 4. CD99 induces apoptotic cell death of OS cells during differentiation. Apoptosis was evaluated by TUNEL assay. The nuclei were counterstainedwith
methyl green.
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Fig. 5. CD99 favors ERK 1/2 activity inducing its localization mainly at plasma membrane and/or in the cytoplasm rather than in the nucleus. (A) Western
blotting analysis of phospho‐ERK (pERK) 1/2 and ERK 1/2 confirmed the higher activation levels during osteoblast differentiation either in hBM‐MSCs or in
OS cells overexpressing CD99. (B, C) Immunofluorescence and Western blotting of cytoplasmic (C) and nuclear (N) fractions further supported higher
expression of the activated ERK 1/2 in CD99‐overexpressing cells comparedwith the parental cell lines. (D) ELK‐1 and AP1 transcriptional activity evaluated
by luciferase reporter gene assay in parental cell lines and CD99 clones. Data are presented as mean SEM of experiments performed in triplicate and
expressed as relative light units (RLU). Values were normalized to Renilla luciferase activity and expressed as fold induction over the negative control.
Student’s t test was used (p< 0.05; p< 0.01).
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Fig. 6. CD99 increases osteogenic stimuli and enhances RUNX2 activity. (A) Immunofluorescence confirmed higher expression of RUNX2 in CD99‐
overexpressing cells compared with controls. For OS cells, analysis was performed in basal conditions (day 0); for hBM‐MSCs, the protein expression was
analyzed during the osteoblast differentiation (day 0 and day 14). Scale bar¼ 20mm. (B) The presence of CD99 in OS cells increased the recruitment of
RUNX2 on OCN and p21WAF1/CIP1 promoters either in basal (day 0) or in differentiating conditions (day 7). Results were quantified and reported as OD ratio
of RUNX2 occupancy on the specific promoter versus input DNA. (C) For Saos‐2 model, enriched DNA was also quantified by qRT‐PCR. Data represent
recovery, in percent, of each DNA fragment relative to total input DNA.~CT¼CT (input)‐ CT (IP) where CT (cycle threshold) is the cycle number at which
each PCR reaction reaches a predetermined fluorescence threshold, set within the linear range of all reactions. Percent recovery¼ 2~CT 2 considering
that the input chromatin was 2% of the total.
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Fig. 7. CD99 regulates RUNX2 activity modulating ERK 1/2 signaling. (A) Expression of CD99 and pERK 1/2 was analyzed by Westen blotting after CD99
silencing for 48 hours by siRNA (40 nM). Cells were transfected by a scrambled (SCR) and a siRNA against p53 (siRNA CTR) as controls at the same
concentration. (B, C) Expression of active ERK 1/2 and RUNX2 was evaluated by immunofluorescence in CD99‐expressing cells in the same conditions
described before. Scale bar¼ 20mm. (D) After CD99 silencing in OS cells for 48 hours, the expression of osteoblast differentiation markers was analyzed:
collagen 1 and ALP decreased, as shown by qRT‐PCR and by histochemical analysis.
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expression of CD99, suggesting a role of this molecule in
osteoblastogenesis. We demonstrated that by restoring CD99
expression to physiologic levels, OS cells differentiate into
mature osteoblasts with concomitant minimization of the tumor
phenotype. The relationship between CD99 and differentiation is
complex but clearly documented at least in hematopoietic
elements with the highest expression among immature
lymphoid and myeloid precursors, particularly in immature
thymic T‐cell precursors and gradual loss along differentia-
tion.(49) Similarly, we have shown progressive loss of CD99
expression when hBM‐MSCs are induced to neural differentia-
tion.(19) In these contexts, CD99 appeared as a marker of
stemness. Interestingly, in related tumors, such as T‐cell acute
lymphoblastic leukemia (ALL), which originates from T cells
arrested at any of the immature stages of development, or in
Ewing’s sarcoma, which derives from undifferentiated pluripo-
tential MSCs, CD99 is highly expressed and acts as an
oncogene.(19,23) In contrast, the protein is maintained during
osteoblast differentiation and increased in lining cells(11) or in
mature osteoblasts. Here, we show that CD99 is pivotal in
controlling the dichotomy between proliferation and differenti-
ation. Although most OS cells can be induced to osteogenic
differentiation program and to production of bone matrix if
cultured in differentiating conditions, they cannot complete the
terminal stages of differentiation, preserving their proliferative
abilities. Conversely, OS cells transfected with CD99 can be
induced to reproduce the physiologic osteogenic program
because they undergo not only expression of typical differentia-
tion markers but also block of proliferation and induction of
apoptosis. One of the possible osteoblast behaviors besides
becoming osteocytes or lining cells is the apoptotic death that
seems required to generate a physiologic signal for bone
resorption and regulation of bone turnover. Thus, it seems that
CD99 can program cell fate in OS toward terminal osteoblast
differentiation to osteocytes or lining cells and that apoptosis
could either be a true end product of terminal differentiation or
with identical death fate, the result of abortive differentiation
once growth arrested.
With a short cytoplasmic tail devoid of signaling motifs except
a site for PKCa phosphorylation,(17) it is unlikely that CD99 could
provide direct signaling. Interactions with other cell surface
molecules are, therefore, assumed to be necessary to regulate its
multiple functions. In OS, CD99 was found to interact with
caveolin‐1 to form a complex that maintains c‐Src in its inactive
conformation.(11,12) Caveolin‐1 has a dual role in sarcomas, thus
mirroring CD99; it is required for osteoblast differentiation but is
downregulated during osteoblast transformation and osteosar-
coma progression.(50) When CD99 is re‐expressed in OS cells,
caveolin‐1 is increased and c‐Src signaling inhibited. Accordingly,
the requirement of c‐Src inhibition for osteoblast differentiation
may partly explain CD99‐induced phenotype. In this article,
however, we provide new evidence that CD99 restoration into
OS cells modulates other important signaling pathways
converging on MAPK/ERK 1/2 and RUNX2 activation. In cells
with high expression of CD99, ERK 1/2 phosphorylation was
constitutively higher compared with parental OS cells, and active
ERK was found to be located at cell membrane and cytoplasm
other than the nucleus. Space‐time control of the MAPK/ERK
signaling pathway is a key factor to determine the specificity of
response in the cell. Although phosphorylation of ERK 1/2 by
growth factors leads to dissociation of ERK from MEK and rapid
translocation into the nucleus where it activates cell proliferation,
in quiescent cells ERK 1/2 is located in the cytoplasm or anchored
at cell membrane, where it targets proteins, such as Myosin Light
Chain Kinase, paxillin, FAK, and connexin43, all involved in cell
migration, cell adhesion, and cell survival.(51) Localization of
active ERK into distinct subcellular compartments has a role in
determining cell fate decisions(44) including thymocytes selec-
tion in the thymus, a tissue characterized by high expression of
CD99.(49) In OS cells, we show that sustained activation of plasma
membrane/cytoplasmic ERK in CD99‐overexpressing cells may
increase activity of RUNX2 and AP1, the latter being another
critical controller of osteogenic genes that acts as a co‐regulator
of RUNX2 itself. In OS cells ectopically expressing CD99, we
demonstrated higher RUNX2 affinity on the promoter of
p21WAF1/CIP1 (a crucial inhibitor of cell proliferation) and of
OCN (a marker of mature osteoblasts) consistently with the
terminal differentiated phenotype observed. The RUNX2 tran-
scription factor has multiple regulatory activities, not only gene
expression activation or repression but also scaffolding of co‐
regulators that establish a hub for the coordination of functions
essential to the expansion and differentiation to the osteogenic
lineage. Toward osteoblast maturation, RUNX2 promotes
osteoblastogenesis and has antiproliferative effects.(52) However,
RUNX2 is also aberrantly expressed in OS owing to amplification
of the chromosomal region 6p12‐21(53) and/or loss of p53
functions, which is permissive for or even contributes to elevated
RUNX2 protein level.(2) Previous studies have shown that RUNX2
interacts specifically with hypophosphorylated pRB during the
early stages of cell cycle withdrawal in terminal osteoblast
differentiation.(9) RUNX2‐pRB‐induced cell cycle exit would not
be possible because of pRb inactivation, a condition common to
50% to 70% of OS,(54) which could lead to uninhibited
proliferation of tumor cells. Re‐expression of CD99 is sufficient
to resume the block of cell proliferation even in the pRb loss of
function. This may again be favored by sustained activation of
ERK 1/2, which likely through BMP‐SMAD‐AP1 signaling and
RUNX2 activity(36) may increase transcriptional activation of
p21WAF1/CIP1, therefore favoring G0/G1 arrest. CD99 did not
immunoprecipitate with ERK 1/2 (data not shown), but evidence
so far collected suggests that CD99 is able to activate multiple
events at the cell membrane, such as modulation of caveolin‐
1,(12) cadherins,(24) increased BMP2 or FGF2 osteogenic signaling
(Supplemental Fig. S7), as well as ECM‐mediated mechanores-
ponse (collagen 1 production is increased in CD99 OS cells).
These varied stimuli inhibit c‐Src(12) while activating MAPK/ERK.
The role of MAPK/ERK in physiologic bone remodeling and
osteoblast differentiation is well known.(42,55) We demonstrated
that unabated MAPK/ERK signaling and its location to cell
membrane/cytoplasm rather that in the nucleus may drive a
differentiated phenotype under specific circumstances also in
tumor cells, challenging the classic paradigm according to which
RAS/MAPK is invariably a primary driver of oncogenic transfor-
mation. It is intriguing that in Ewing’s sarcoma, where the
expression of CD99 is high and the molecule acts as an
oncogene, the achievement of a terminally differentiated
phenotype requires the loss of CD99 but still the persistent
activation of ERK,(19) further confirming the crucial role of this
pathway in the differentiation of sarcomas. The fact that CD99
activates pathways favoring normal cell differentiation may be
considered a further confirmation of its importance in the
reversal of malignancy of sarcoma cells.
In summary, we have shown that CD99 deficiency is required
for OS oncogenic phenotype. Restoration of CD99 expression at
the physiologic levels in OS cells affects their malignancy
potential(11,12) and results in the achievement of a terminally
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differentiated phenotype also in the genetically compromised
OS cells. CD99 activates pathways that target ERK 1/2 to the cell
membrane/cytoplasm, connecting it with increased activity of
major osteogenic transcriptional factors, such as AP1 and RUNX2.
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